BioMedomics CoV-SCAN Rapid Antigen Test demonstrated high sensitivity and specificity for numerous SARS-CoV-2 variants, including Omicron and Delta, in a peer-reviewed point-of-care clinical evaluation

Recently published in the highly regarded, peer-reviewed Journal of Clinical Virology Plus, a clinical point-of-care and laboratory trial, performed in conjunction with the Columbia University Irving Medical School, demonstrated the ability of the BioMedomics CoV-SCAN Rapid Antigen Test to detect SARS-CoV-2 variants with high sensitivity and specificity. These results are due to CoV-SCAN’s unique design, using 4 unique antibodies to detect SARS-CoV-2.

In laboratory testing, CoV-SCAN detected 14 variants, including Omicron and Delta, with similar sensitivity to the wild-type virus; CoV-SCAN did not cross-react with any other human coronaviruses.

In clinical point-of-care (POC) testing on 148 individuals over age 2 with symptom onset of less than or equal to 5 days, CoV-SCAN detected SARS-CoV-2 in 87.2% of COVID-19 infected individuals and did not misdiagnose any non-infected individuals. In another 884 asymptomatic individuals, CoV-SCAN detected 85.7% of COVID-19 infected individuals and correctly diagnosed 99.7% of non-infected individuals.

Importantly, CoV-SCAN detected SARS-CoV-2 in greater than 97.2% of patient specimens with CT values < 30, a well-established clinically meaningful cutoff for infectivity.

These results demonstrate that CoV-SCAN should detect SARS-CoV-2 variants, known and unknown, in almost all individuals harboring infectious quantities of COVID-19. Additionally, CoV-SCAN’s high specificity makes it incredibly useful for the early identification of new infectious clusters before they become hotspots.

To read the full article please click here